Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135496 | 1.00 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31164313 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL16379393 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31164312 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15160681 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL6036899 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Bromide SCHEMBL15809407 | 0.99 | KMT2A (0.71) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15160677 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15155687 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31164311 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564650-B2 | Carbonic anhydrase IX-targeting radioactive diagnostic and therapeutic medicament and method for preparing same | NORROY BIOSCIENCE CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20240415988-A1 | CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAME | NORROY BIOSCIENCE CO., LTD. (CN) | 2024-12-19 | — | — | US | disclosed |
| CN-117186087-A | Carbonic anhydrase IX targeted radioactive diagnosis and treatment medicine and preparation method thereof | 无锡诺宇医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023155454-A1 | CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAME | 无锡诺宇医药科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| US-20230256080-A1 | VACCINE AND THERAPEUTIC COMPOSITIONS COMPRISING ANTIGEN-CONJUGATED VIRAL CAPSIDS | UNIV MICHIGAN STATE (US) | 2023-08-17 | — | — | US | disclosed |
| US-11576957-B2 | Vaccine and therapeutic compositions comprising antigen-conjugated viral capsids | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| CN-111569083-A | Targeting vector suitable for African swine fever virus resistant siRNA (small interfering ribonucleic acid) medicine and application thereof | 杭州勇诚睿生物科技有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-20200261559-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER AND INFECTIONS USING BACTERIOPHAGE AND ITS MUTANTS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2020-08-20 | — | — | US | disclosed |
| CN-111514307-A | Novel liver targeting drug carrier | 杭州勇诚睿生物科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3675902-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER AND INFECTIONS USING BACTERIOPHAGE AND ITS MUTANTS | Board of Trustees of Michigan State University (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| US-6949679-B1 | Polyamine transport inhibitors | UNIVERSITE LAVAL (CA) | 2005-09-27 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| WO-2000034226-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-06-15 | — | — | WO | disclosed |
| EP-1003715-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999054283-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1999-10-28 | — | — | WO | disclosed |
| EP-0876327-A2 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998017623-A2 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261559-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER AND INFECTIONS USING BACTERIOPHAGE AND ITS MUTANTS | TP53, COIL, COPE | KMT2A 1162/4885EPHX2 4049/4885TLR2 192/4885 |
| US-12564650-B2 | Carbonic anhydrase IX-targeting radioactive diagnostic and therapeutic medicament and method for preparing same | CA9, CA12, CA13 | KMT2A 2644/4885EPHX2 2196/4885TLR2 4498/4885 |
| US-20240415988-A1 | CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAME | CA9, CA14, CA13 | KMT2A 2087/4885EPHX2 836/4885TLR2 4820/4885 |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | KMT2A 4390/4885EPHX2 2508/4885TLR2 552/4885 |
| US-20230256080-A1 | VACCINE AND THERAPEUTIC COMPOSITIONS COMPRISING ANTIGEN-CONJUGATED VIRAL CAPSIDS | TP53, LY96, BLK | KMT2A 1046/4885EPHX2 4454/4885TLR2 216/4885 |
| US-11576957-B2 | Vaccine and therapeutic compositions comprising antigen-conjugated viral capsids | TP53, MAPT, SPAG5 | KMT2A 1665/4885EPHX2 4357/4885TLR2 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.